What do systematic reviews say?

Ketamine vs midazolam

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Memantine vs placebo

Memantine showed no clear difference in acceptability: total dropouts compared with placebo (low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 0.77 [0.45, 1.31]
  2 studies · 261 participants
  Low

Cytidine vs placebo

It is very uncertain whether cytidine changes acceptability: total dropouts compared with placebo (very low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 0.94 [0.12, 7.52]
  1 study · 35 participants
  Very low

Riluzole vs placebo

It is very uncertain whether riluzole changes acceptability: total dropouts compared with placebo (very low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 2 [0.31, 12.84]
  1 study · 19 participants
  Very low

Ketamine vs placebo

It is very uncertain whether ketamine changes acceptability: total dropouts compared with placebo (very low certainty).

• Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  OR 3.48 [0.56, 21.74]
  2 studies · 33 participants
  Very low

Mobile technologies used by primary care providers to consult with a hospital‐based specialist vs usual care

The review found no eligible studies for this question.

• Mobile technologies to support healthcare provider to healthcare provider communication and management of care 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5.3% HP strip vs 5% HP gel in tray

It is very uncertain whether 5.3% HP strip changes patient comfort / acceptability compared with 5% HP gel in tray (very low certainty).

• Home‐based chemically‐induced whitening (bleaching) of teeth in adults 2018 · Cochrane All outcomes
  MD 1.27 [0.13, 2.41]
  1 study · 28 participants
  Very low

Lithium vs valproate

Lithium showed no clear difference in acceptability: total withdrawals compared with valproate (high certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.2 [0.86, 1.69]
  5 studies · 629 participants
  High

Lithium vs lamotrigine

It is very uncertain whether lithium changes acceptability: total withdrawals compared with lamotrigine (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.8 [0.5, 1.29]
  3 studies · 303 participants
  Very low

Lithium vs carbamazepine

Lithium showed no clear difference in acceptability: total withdrawals compared with carbamazepine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.2 [0.02, 1.94]
  1 study · 34 participants
  Low

Lithium vs QUETIAPINE

It is very uncertain whether lithium changes acceptability: total withdrawals compared with quetiapine (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.38 [0.83, 2.28]
  2 studies · 359 participants
  Very low

Lithium vs OLANZAPINE

Lithium may leads to higher acceptability: total withdrawals compared with olanzapine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 2.6 [1.13, 5.99]
  3 studies · 210 participants
  Low

Lithium vs placebo

Lithium showed no clear difference in acceptability: total withdrawals compared with placebo (moderate certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.76 [0.46, 1.25]
  7 studies · 1353 participants
  Moderate

Lithium vs chlorpromazine

Lithium showed no clear difference in acceptability: total withdrawals compared with chlorpromazine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.75 [0.92, 3.31]
  2 studies · 262 participants
  Low

Lithium vs haloperidol

It is very uncertain whether lithium changes acceptability: total withdrawals compared with haloperidol (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.29 [0.03, 3.12]
  1 study · 30 participants
  Very low

Lithium vs Zuclopenthixol (Cis Z/Trans E isomer)

It is very uncertain whether lithium changes acceptability: total withdrawals compared with zuclopenthixol (very low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.78 [0.17, 3.49]
  1 study · 28 participants
  Very low

Lithium vs RISPERIDONE

Lithium probably leads to higher acceptability: total withdrawals compared with risperidone (moderate certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.85 [1.02, 3.34]
  3 studies · 255 participants
  Moderate

Lithium vs ARIPIPRAZOLE

Lithium showed no clear difference in acceptability: total withdrawals compared with aripiprazole (moderate certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 0.94 [0.6, 1.46]
  1 study · 315 participants
  Moderate

Lithium vs topiramate

Lithium showed no clear difference in acceptability: total withdrawals compared with topiramate (high certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.28 [0.66, 2.48]
  2 studies · 1352 participants
  High

Lithium vs clonazepam

The review found no eligible studies for this question.

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found